Skip to main content
Clinical Trials/DRKS00034041
DRKS00034041
Recruiting
未知

Clinical study to assess the long-term effect of a mixture ofplant extracts on glucose homeostasis in prediabetic subjects: a 12-week randomized, double-blind, placebo-controlled, parallel study

APOMEDICA Pharmazeutische Produkte GmbH0 sites42 target enrollmentApril 15, 2024

Overview

Phase
未知
Intervention
Not specified
Conditions
prediabetes
Sponsor
APOMEDICA Pharmazeutische Produkte GmbH
Enrollment
42
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
April 15, 2024
End Date
TBD
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Main inclusion criteria:
  • \- Male and female subjects with prediabetic HbA1c values between 5\.7% – 6\.4% and/or fasting glucose \= 5\.6 mmol/L (\= 100 mg/dL) and \= 6\.9 mmol/L (\= 125 mg/dL) (in venous plasma) (twice confirmed at two independent days if HbA1c is \< 5\.7%)
  • \- Body mass index 19\-35 kg/m2
  • \- Current Non\-smoker
  • \- Signed informed consent form
  • \- No changes in food habits or physical activity 3 months prior to screening and during the study
  • \- If applicable, stable intake of chronic medication of at least 4 weeks

Exclusion Criteria

  • Main Exlusion criteria:
  • \- Diagnosed type 2 diabetes mellitus with medical treatment
  • \- Presence of disease or drug(s) influencing digestion and absorption of nutrients
  • \- Intake of medications known to affect glucose tolerance, e.g. diabetic medication, SGLT\-2 inhibitors, GLP\-1 receptor agonists, steroids, protease inhibitors or antipsychotics
  • \- Known inflammatory and malignant gastrointestinal diseases (i.e. colitis ulcerosa, Morbus Crohn, celiac disease, malignant diseases e.g. colon\-cancer, rectum cancer, pancreatitis)
  • \- Chronic intake of substances affecting blood coagulation (e.g. acetylic acid (100 mg as standard prophylactic treatment allowed when dose is stable 1 month prior to screening), anticoagulants, diuretics, thiazides (diuretics and thiazides allowed e.g. for hypertension treatment when dose is stable 1 month prior to screening)), which in the Investigator’s opinion would impact patient safety
  • \- Severe liver or renal disease or laboratory evidence of hepatic dysfunction (i.e. alkaline phosphatase, ALT, AST \>3 x ULN)
  • \- Acute gastrointestinal diseases including diarrhea and/or vomiting within the last 2 weeks
  • \- Clinically relevant findings as established by medical history, physical examination, clinical laboratory and/or vital signs
  • \- Intake of food supplements known to affect glucose tolerance, e.g. cinnamon capsules, conjugated linoleic acids within 4 weeks prior to Visit 1 or during the study

Outcomes

Primary Outcomes

Not specified

Similar Trials